SuperworthVericel profit margin VCEL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- 7.9%
- Operating margin, 12 months
- 6.0%
- Net margin on a year earlier
- +5.1 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Vericel kept 7.9% of its revenue as net profit, with an operating margin of 6.0% and a gross margin of 74.6%.
Five years earlier its net margin was 5.8%.
The median for 8 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 6.0% | 4.0% | 74.4% |
| FY2024 | 4.4% | 1.9% | 72.6% |
| FY2023 | −1.6% | −3.3% | 68.6% |
| FY2022 | −10.2% | −10.4% | 66.8% |
| FY2021 | −4.8% | −5.0% | 67.9% |
| FY2020 | 2.3% | 1.9% | 67.8% |
| FY2019 | −8.2% | −9.5% | 68.1% |
| FY2018 | −9.0% | −4.3% | 64.6% |
| FY2017 | −27.0% | −23.4% | 52.5% |
| FY2016 | −36.0% | −35.4% | 47.9% |
| FY2015 | −31.9% | −32.6% | 48.3% |
| FY2014 | −69.2% | −81.7% | 39.9% |
| FY2013 | n/a | n/a | 78.9% |
| FY2012 | n/a | n/a | 71.4% |
| FY2011 | n/a | n/a | 77.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 7.9% | +5.1 pts | 6.0% | |
| Q1 FY26 | 7.3% | +6.1 pts | 5.4% | |
| Q4 FY25 | 6.0% | +1.6 pts | 4.0% | |
| Q3 FY25 | 5.1% | +3.5 pts | 2.7% | |
| Q2 FY25 | 2.9% | +2.5 pts | 0.5% | |
| Q1 FY25 | 1.2% | +1.0 pts | −1.2% | |
| Q4 FY24 | 4.4% | +6.0 pts | 1.9% | |
| Q3 FY24 | 1.6% | +7.1 pts | −0.5% | |
| Q2 FY24 | 0.4% | +7.8 pts | −1.8% | |
| Q1 FY24 | 0.2% | +10.3 pts | −1.8% | |
| Q4 FY23 | −1.6% | +8.6 pts | −3.3% | |
| Q3 FY23 | −5.5% | +5.8 pts | −7.1% |
Against its peers
Companies in Biotechnology nearest Vericel's size, closest first, today.
| Company | Profit margin |
|---|---|
| VCELVericel | 7.9% |
| ADMAAdma Biologics | 33.0% |
| MGTXMeiraGTx | 19.9% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| Peer median | 22.9% |
Where Vericel ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Vericel
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.